Navigation Links
Mylan One of First to Launch Generic Version of Boniva®
Date:3/20/2012

PITTSBURGH, March 20, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Ibandronate Sodium Tablets, 150mg. This product is the generic version of Roche's Boniva®, which is indicated for the treatment and prevention of osteoporosis in postmenopausal women.

Boniva® had U.S. sales of approximately $517 million for the 12 months ending Dec. 31, 2011, according to IMS Health. Mylan is shipping the product immediately.

Currently, Mylan has 173 ANDAs pending FDA approval representing $100.9 billion in annual sales, according to IMS Health. Forty-two of these pending ANDAs are potential first-to-file opportunities, representing $27.4 billion in annual brand sales, for the 12 months ending December 31, 2011, according to IMS Health.

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com. For more information about generic drugs, please visit www.ChoosingGenerics.com.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Mylan Canada Receives Health Canada Approval for Generic Version of Crestor®
2. Mylan Continues to Pursue Damages and Injunction Against Sunovions Brovana® in Ongoing Litigation
3. Mylan Pharmaceuticals President Tony Mauro Elected Chairman of GPhA
4. Mylan Secures an Additional $300 Million of Committed Financing
5. Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
6. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
7. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
8. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
9. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
10. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
11. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... NEWARK, N.J. , Aug. 27, 2015  Symbiomix ... Phase 3 clinical study, the second pivotal trial of ... the treatment of bacterial vaginosis (BV). Earlier this year ... for SYM-1219. Symbiomix expects to finish this second pivotal ... a New Drug Application (NDA) filing with the U.S. ...
(Date:8/27/2015)... -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN ) today announced that ... a corporate overview and business update at two investor conferences ... . , 22 nd Annual NewsMakers in ... Millennium Broadway Hotel. , Rodman & Renshaw Annual Global ... Regis Hotel. To access the live audio webcast ...
(Date:8/26/2015)... PUNE, India , August 27, 2015 ... market research reports reviewing the genotyping technology, ... as well as single nucleotide polymorphism (SNP) ... ReportsnReports.com. Complete report on genotyping ... spread across 200 pages, profiling 10 major ...
Breaking Medicine Technology:Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 2Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 3Symbiomix Therapeutics Completes Enrollment in Second Pivotal Trial of SYM-1219 for Bacterial Vaginosis, and Receives FDA Fast Track Designation 4SciClone To Present At Two Investor Conferences On September 10, 2015 2Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 2Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 3Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 4Genotyping Market Forecast to Grow at 22.3% CAGR to 2020 5
... The law firm of Childers, Schlueter & Smith, LLC of ... will be held during the week of July 26, 2010 .  The ... States District Court, Northern District of Georgia , Atlanta Division. , ... The lawsuit alleges that the drug makers and ...
... Inc. (NYSE Amex: MHH ) ("Mastech"), a national provider of Information Technology ... discuss the results of its second quarter ended June 30, 2010 . ... 9:00 a.m. Eastern Time and will be hosted by Mr. ... , , ...
Cached Medicine Technology:Childers, Schlueter & Smith, LLC Set for Reglan/metoclopramide Jury Trial Involving Woman's Development of Tardive Dyskinesia 2Mastech Holdings, Inc. to Discuss Second Quarter 2010 Financial Results on July 28, 2010 2
(Date:8/27/2015)... ... August 27, 2015 , ... ... scheduled for October 27-29, 2015 in San Jose, CA. The first event ... focus on the void that exists where battery development and energy storage innovation ...
(Date:8/27/2015)... ... August 27, 2015 , ... In addition to its existing Doctor ... a third doctoral program at its main campus in Reading: Doctor of Nursing Practice. ... designed to prepare advanced practice nurses for the highest level of clinical nursing practice. ...
(Date:8/27/2015)... ... ... Pinellas, located at 1395 South Pinellas Avenue in Tarpon Springs, will open a free-standing emergency ... at US Highway 19 North and Highlands Boulevard, less than eight miles from the main ... is slated to begin in September 2015. , The new 24-bed facility will ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... NetDimensions ... , “The companies selected have the platforms required not only to effectively deliver, curate ... Taylor, President of Training Industry, Inc. , For six consecutive years, NetDimensions has ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... they have launched their new corporate website http://www.Z-Medica.com , to further support ... website that was launched last year. , “We launched a branded website ...
Breaking Medicine News(10 mins):Health News:Infocast Hosting First Conference Dedicated to Powering Wearable Devices & the IoT 2Health News:Alvernia University Now Offering Three Doctoral Degree Programs 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:Z-Medica® Launches New Corporate Website 2
... Heavy alcohol consumption, specifically three or more glasses of ... of death from pancreatic cancer, according to a report ... Internal Medicine, one of the JAMA/Archives journals. ... is causally related to several cancers, including oral cavity, ...
... , , , , ... AUDIO: Washington University,s Victoria Fraser, MD, talks about ... , , , , ... , , , , , , ...
... March 14 (HealthDay News) -- A lack of vitamin ... but levels of the vitamin don,t decrease as the ... insufficiency has been associated with a variety of clinical ... strength, mood and cognitive dysfunction, autoimmune disorders such as ...
... HealthDay Reporter , MONDAY, March 14 (HealthDay News) -- Women ... fatty acids found in that meal choice -- have a ... suggests. This latest evidence of a protective link between ... found the same benefit. In this study, Harvard researchers performed ...
... March 14, 2011 -- Some physicians are prescribing opioids such ... a new study led by St. Michael,s Hospital and the ... opioid-related deaths occur among patients treated by physicians who frequently ... may not be doing so safely. "We found that ...
... technique called microdissection testicular sperm extraction (TESE) can effectively ... of adult male childhood cancer survivors who were previously ... result, many of the men were subsequently able to ... The findings offer a new option for many cancer ...
Cached Medicine News:Health News:Heavy drinking associated with increased risk of death from pancreatic cancer 2Health News:Novel strategies target health care-associated infections 2Health News:Novel strategies target health care-associated infections 3Health News:Novel strategies target health care-associated infections 4Health News:Study: Lack of Vitamin D May Precede Onset of Parkinson's 2Health News:Eating Fish Might Protect Your Eyesight 2Health News:Eating Fish Might Protect Your Eyesight 3Health News:Painkiller prescribing varies dramatically among family physicians: study 2Health News:Surgical technique helps adult male survivors of childhood cancer regain fertility 2Health News:Surgical technique helps adult male survivors of childhood cancer regain fertility 3
... (IGF-I or somatomedin C) is a 7.6 kDa ... as a potent mitogen of cellular proliferation, exerting ... In the circulation, IGF-I is bound to IGF-binding ... of IGF-I by modulating the interaction of IGF-I ...
Inquire...
... table comes in two modelsthe BT4, which ... BT5, which offers five. With the simple ... to suit your needs. Both models ... side rails, ankle/foot supports, adjustable arm boards, ...
... A revolutionary urological imaging system ... that translate into improved patient ... 1k imaging technology physicians and ... see more anatomical detail and ...
Medicine Products: